Michael Barbella, Managing Editor04.29.23
Testing and treatment were top priorities for MPO website viewers this past week.
Cyber visitors particularly were interested in diabetes and coronary heart disease testing, as well as an artificial intelligence-driven method for detecting fatty liver disease.
Leading the charge was the U.S. launch of Orange Biomed's OBM rapid A1c test, reportedly the world’s first glycated hemoglobin analyzer that uses single-cell analysis of red blood cells. OBM rapid A1c is a portable, guided, five-minute test requiring only a single drop of blood to produce accurate results.
Cardio Diagnostics Holdings Inc. attracted quite a following with its launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. PrecisionCHD is the second clinical test built using Cardio Diagnostics’ proprietary artificial intelligence-driven Integrated Epigenetic-Genetic Engine. The company’s initial product, Epi+Gen CHD, a three-year coronary heart disease risk assessment test, also leveraged the Engine and was launched in 2021. The two tests address the most common form of cardiovascular disease—coronary heart disease—across the entire spectrum, from assessing risk for prevention to early detection.
Artificial intelligence also plays a central role in NuraLogix's fatty liver disease detection technology, a clear favorite among website loyalists. Company researchers have devised AI models that can predict a person’s risk of developing fatty liver disease (FLD) using facial blood flow patterns. This is the latest capability of the company’s Anura contactless health platform that can take more than 30 medical-grade health vitals and numerous health risk assessments using any video-enabled device. In their latest study, NuraLogix researchers trained their machine learning models on the facial blood flow patterns of more than 7,000 subjects with FLD. The data showed the models’ capability to predict whether a subject had FLD with an AUC > 0.85, suggesting a high degree of accuracy. This follows the recent expansion of the platform’s capability to potentially monitor HbA1c, fasting glucose, as well as the risk of type 2 diabetes, hypertension, and hypertriglyceridemia.
Glooko and Sanofi amassed considerable page views this past week with their joint effort to improve diabetes treatment support, while ATL Technology gained a following by purchasing the manufacturing operations of Gyrus Medical Limited from Olympus Winter & Ibe GmbH (Olympus Surgical Technologies Europe). Gyrus, located in Cardiff, Wales, United Kingdom, is also a device outsourcer and will increase both ATL’s global footprint and capabilities.
The Glooko-Sanofi partnership will integrate the latter's SoloSmart with the Glooko platform. SoloSmart is a single piece add-on connected device intended for use with SoloStar and DoubleStar insulin injection pens that records the insulin dose, date and time of injection and allows for visualization of the data in the Glooko app, so patients can share with healthcare professionals. SoloSmart is not yet approved in the United States.
Cyber visitors particularly were interested in diabetes and coronary heart disease testing, as well as an artificial intelligence-driven method for detecting fatty liver disease.
Leading the charge was the U.S. launch of Orange Biomed's OBM rapid A1c test, reportedly the world’s first glycated hemoglobin analyzer that uses single-cell analysis of red blood cells. OBM rapid A1c is a portable, guided, five-minute test requiring only a single drop of blood to produce accurate results.
Cardio Diagnostics Holdings Inc. attracted quite a following with its launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. PrecisionCHD is the second clinical test built using Cardio Diagnostics’ proprietary artificial intelligence-driven Integrated Epigenetic-Genetic Engine. The company’s initial product, Epi+Gen CHD, a three-year coronary heart disease risk assessment test, also leveraged the Engine and was launched in 2021. The two tests address the most common form of cardiovascular disease—coronary heart disease—across the entire spectrum, from assessing risk for prevention to early detection.
Artificial intelligence also plays a central role in NuraLogix's fatty liver disease detection technology, a clear favorite among website loyalists. Company researchers have devised AI models that can predict a person’s risk of developing fatty liver disease (FLD) using facial blood flow patterns. This is the latest capability of the company’s Anura contactless health platform that can take more than 30 medical-grade health vitals and numerous health risk assessments using any video-enabled device. In their latest study, NuraLogix researchers trained their machine learning models on the facial blood flow patterns of more than 7,000 subjects with FLD. The data showed the models’ capability to predict whether a subject had FLD with an AUC > 0.85, suggesting a high degree of accuracy. This follows the recent expansion of the platform’s capability to potentially monitor HbA1c, fasting glucose, as well as the risk of type 2 diabetes, hypertension, and hypertriglyceridemia.
Glooko and Sanofi amassed considerable page views this past week with their joint effort to improve diabetes treatment support, while ATL Technology gained a following by purchasing the manufacturing operations of Gyrus Medical Limited from Olympus Winter & Ibe GmbH (Olympus Surgical Technologies Europe). Gyrus, located in Cardiff, Wales, United Kingdom, is also a device outsourcer and will increase both ATL’s global footprint and capabilities.
The Glooko-Sanofi partnership will integrate the latter's SoloSmart with the Glooko platform. SoloSmart is a single piece add-on connected device intended for use with SoloStar and DoubleStar insulin injection pens that records the insulin dose, date and time of injection and allows for visualization of the data in the Glooko app, so patients can share with healthcare professionals. SoloSmart is not yet approved in the United States.
